GGrantIndex
← Leaderboards

Lars Bode

Sanford Burnham Prebys Medical Discovery Institute

Google Scholar ↗PubMed ↗ORCID ↗
$5,602,006
Attributed
$5,915,131
Total exposure
13
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $8.4M · FY2008–25
$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,021,629 · 14

By mechanism

P50$15,115,334 · 2
R21$2,460,837 · 6
R01$1,192,137 · 1
R00$746,828 · 1
R43$200,000 · 1
K99$181,080 · 1

Top collaborators

Others in their field

Top investigators on “Infant”

Research focus

InfantOligosaccharidesHuman MilkBreast FeedingMothersMilkSamplingResourcesResponseChildhoodBreastfed InfantEnzymesComplexProgramsLeadTechnologyResearch Project GrantsIn VivoMetabolomicsNeonatalMicrobiomeHigh Pressure Liquid ChromatographyCollaborationsPharmaceutical Preparations

Grant awards (40)

Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,190,453
P50 · FY2025 · HD
Milk Analytics Core$199,631
P50 · FY2025 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$3,465,000
P50 · FY2024 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$3,465,000
P50 · FY2024 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,231,207
P50 · FY2024 · HD
Milk Analytics Core$201,167
P50 · FY2024 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,239,102
P50 · FY2023 · HD
Milk Analytics Core$202,621
P50 · FY2023 · HD · contact PI
Origins and Benefits of Biologically Active Components in Human Milk$10,000
R13 · FY2023 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,250,000
P50 · FY2022 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,015,736
P50 · FY2022 · HD
Milk Analytics Core$200,271
P50 · FY2022 · HD · contact PI
Exploring Associations between Human Milk Oligosaccharides and Atherosclerosis Risk Factors in Infancy and Early Childhood$171,743
R21 · FY2022 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,250,000
P50 · FY2021 · HD
Exploring Associations between Human Milk Oligosaccharides and Atherosclerosis Risk Factors in Infancy and Early Childhood$225,959
R21 · FY2021 · HD · contact PI
Milk Analytics Core$205,146
P50 · FY2021 · HD · contact PI
Exploring human milk oligosaccharides and malaria risk in breastfed infants$170,000
R21 · FY2021 · AI · contact PI
Exploring human milk oligosaccharides and malaria risk in breastfed infants$201,156
R21 · FY2020 · AI · contact PI
Exploring The Impact of Human Milk Oligosaccharides in Atherosclerosis$193,750
R21 · FY2018 · HD
Exploring Associations between Human Milk Oligosaccharides and Growth, Body Composition and Obesity Risk in Infancy and Early Childhood$181,972
R21 · FY2018 · HD · contact PI
Exploring Associations between Human Milk Oligosaccharides and Growth, Body Composition and Obesity Risk in Infancy and Early Childhood$232,570
R21 · FY2017 · HD · contact PI
Exploring The Impact of Human Milk Oligosaccharides in Atherosclerosis$232,500
R21 · FY2017 · HD
Selective Inhibitors of Plasmodium Falciparum G6PD as Novel Antimalarials$379,448
R01 · FY2016 · AI · contact PI
Exploring Oligosaccharide Synthesis in Human Mammary Gland Epithelial Cells$191,812
R21 · FY2016 · HD · contact PI
Selective Inhibitors of Plasmodium Falciparum G6PD as Novel Antimalarials$397,976
R01 · FY2015 · AI · contact PI
Exploring Oligosaccharide Synthesis in Human Mammary Gland Epithelial Cells$232,500
R21 · FY2015 · HD · contact PI
Disialyl oligosaccharides as Necrotizing Enterocolitis therapeutics$200,000
R43 · FY2015 · HD
Selective Inhibitors of Plasmodium Falciparum G6PD as Novel Antimalarials$414,713
R01 · FY2014 · AI · contact PI
Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing Enterocolitis$246,511
R00 · FY2011 · DK · contact PI
Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing Enterocolitis$249,000
R00 · FY2010 · DK · contact PI
Identification of G6PD inhibitors for the development of novel antimalarial drugs$233,379
R21 · FY2010 · AI · contact PI
Screening for Human Milk Oligosaccharides that Protect Infants from HIV Infection$25,000
R03 · FY2010 · HD · contact PI
Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing Enterocolitis$2,318
R00 · FY2010 · DK · contact PI
Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing Enterocolitis$248,999
R00 · FY2009 · DK · contact PI
Identification of G6PD inhibitors for the development of novel antimalarial drugs$193,496
R21 · FY2009 · AI · contact PI
Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing Enterocolitis$90,000
K99 · FY2009 · DK · contact PI
Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing Enterocolitis$1,080
K99 · FY2009 · DK · contact PI
Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing Enterocolitis$90,000
K99 · FY2008 · DK · contact PI
Screening for Human Milk Oligosaccharides that Protect Infants from HIV Infection$68,877
R03 · FY2008 · HD · contact PI
Screening for Human Milk Oligosaccharides that Protect Infants from HIV Infection$21,536
R03 · FY2008 · HD · contact PI